Camptothecin and topotecan, inhibitors of transcription factor Fli ‐1 and topoisomerase, markedly ameliorate lupus nephritis in NZBWF1 mice and reduce the production of inflammatory mediators in human renal cells

ConclusionThe results indicate that low dose CPT and TPT could be repurposed to treat lupus nephritis.

Source: Arthritis and Rheumatology - February 9, 2021 Category: Rheumatology Authors: Xuan Wang, Jim C. Oates, Kristi L. Helke, Gary S. Gilkeson, Xian K. Zhang Tags: FULL LENGTH Source Type: research